ESMO 2020 | Thyroid cancer at ESMO 2020

Mimi Hu, MD University of Texas MD Anderson Cancer Center, Houston, Texas, talks on the ARROW trial (NCT03037385), the only study that discussed thyroid cancer at ESMO 2020. Prof. Hu goes on to discuss a colloquium in which different trials have investigated RET as a target, RET in thyroid cancer, and RET being a potential tumor-agnostic target by using RET as an indication for drug therapy regardless of whether patients have RET aberrations. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).